Billionaire John Paulson’s merger strategy has gained 10 percent this year lifted by consolidation among drugmakers. The $19.3 billion New York-based firm posted a 0.7 percent return last month in a merger fund that uses leverage to amplify gains, according to three people familiar with the matter, who asked not to be identified because the information is private. An unlevered version rose 0.3 in March and is up 4.5 percent this year. [Bloomberg]
Three-And-A-Half Feet Of Snow, Frigid Temperatures Can’t Cool Off John Paulson
Last month was good to JP.
Whatever Doesn't Kill John Paulson Makes Him Stronger
At this point, the hedge fund manager could bench press a dozen Bloomberg terminals.